TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.

Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL/TNFSF10) has been reported to specifically induce malignant cell death being relatively nontoxic to normal cells. Since its identification 15 years ago, the antitumor activity and therapeutic value of TRAIL have been extensively studied. Five receptors quickly emerged, two of them being able to induce programmed cell death in tumor cells. This review takes a comprehensive look at this ligand and its receptors, and its potential role in primary bone tumors (osteosarcoma and Ewing's sarcoma) therapy. The main limit of clinical use of TRAIL being the innate or acquired resistance mechanisms, different possibilities to sensitize resistant cells are discussed in this review, together with the impact of bone microenvironment in the regulation of TRAIL activity.

[1]  Bart Barlogie,et al.  Advances in Biology and Therapy of Multiple Myeloma , 2013, Springer New York.

[2]  P. Secchiero,et al.  Trail down‐regulates the release of osteoprotegerin (OPG) by primary stromal cells , 2011, Journal of cellular physiology.

[3]  Yi Yan Yang,et al.  Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. , 2011, Molecular bioSystems.

[4]  A. Kondo,et al.  THE PRESENCE OF TRAIL–OPG COMPLEX IN HUMAN OSTEOSARCOMA AND HUMAN SALIVARY GLAND ADENOCARCINOMA , 2011, Journal of immunoassay & immunochemistry.

[5]  J. Vose,et al.  A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma , 2010, British Journal of Cancer.

[6]  S. Burchill,et al.  Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours , 2010, British Journal of Cancer.

[7]  A. Ashkenazi,et al.  New insights into apoptosis signaling by Apo2L/TRAIL , 2010, Oncogene.

[8]  E. Kleinerman,et al.  Platelet‐derived growth factor receptor β inhibition increases tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) sensitivity , 2010, Cancer.

[9]  M. De Waard,et al.  Doxorubicin coupled to penetratin promotes apoptosis in CHO cells by a mechanism involving c-Jun NH2-terminal kinase. , 2010, Biochemical and biophysical research communications.

[10]  O. Delattre,et al.  Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival , 2010, Clinical Cancer Research.

[11]  V. Nicolin,et al.  Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231. , 2010, Acta histochemica.

[12]  David M. Thomas,et al.  Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. , 2010, The Lancet. Oncology.

[13]  H. Wakelee,et al.  Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  V. Heinemann,et al.  Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer , 2010, British Journal of Cancer.

[15]  G. Moriceau,et al.  Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. , 2010, Biochimica et biophysica acta.

[16]  O. Surova,et al.  Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL , 2010, Molecular Cancer.

[17]  Gen Sheng Wu.  TRAIL as a target in anti-cancer therapy. , 2009, Cancer letters.

[18]  M. von Mehren,et al.  Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Sleijfer,et al.  Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study , 2009, Clinical Cancer Research.

[20]  Tain‐Hsiung Chen,et al.  Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients. , 2009, Japanese journal of clinical oncology.

[21]  Lisa Mirabello,et al.  International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons , 2009, International journal of cancer.

[22]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[23]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[24]  F. Abdel-Sater,et al.  Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. , 2009, The Biochemical journal.

[25]  K. Kelly,et al.  Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. , 2008, Lung cancer.

[26]  R. Stahel,et al.  TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. , 2008, Lung cancer.

[27]  S. Keir,et al.  Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[28]  A. Oza,et al.  A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.

[29]  P. Chaudhary,et al.  Proteasome inhibitor Bortezomib induces cell-cycle arrest and apoptosis in cell lines derived from Ewing’s sarcoma family of tumors and synergizes with TRAIL , 2008, Cancer biology & therapy.

[30]  D. Lawrence,et al.  Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 , 2008, Cell Death and Differentiation.

[31]  G. Longton,et al.  TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. , 2008, The Journal of clinical investigation.

[32]  A. Klein-Szanto,et al.  TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. , 2008, The Journal of clinical investigation.

[33]  Xin Lin,et al.  Positive and negative signaling components involved in TNFα-induced NF-κB activation , 2008 .

[34]  T. Griffith,et al.  DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells , 2007, Cancer Gene Therapy.

[35]  P. Hulley,et al.  Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis , 2007, Molecular Cancer Therapeutics.

[36]  T. Griffith,et al.  TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. , 2007, International journal of radiation oncology, biology, physics.

[37]  P. Croucher,et al.  Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. , 2007, The Journal of biological chemistry.

[38]  R. Plummer,et al.  Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers , 2007, Clinical Cancer Research.

[39]  G. Cohen,et al.  Barriers to effective TRAIL-targeted therapy of malignancy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  G. Cavet,et al.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.

[41]  M. Papageorgiou,et al.  Bone marrow stromal cells promote growth and survival of prostate cancer cells. , 2007, Biochemical Society transactions.

[42]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[43]  K. Flaherty,et al.  Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. , 2007, Cancer cell.

[44]  Lauren Long,et al.  Interferon- (cid:1) Sensitizes Resistant Ewing’s Sarcoma Cells to Tumor Necrosis Factor Apoptosis-Inducing Ligand-Induced Apoptosis by Up-Regulation of Caspase-8 Without Altering Chemosensitivity , 2007 .

[45]  U. Völker,et al.  Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells , 2007, Journal of Cancer Research and Clinical Oncology.

[46]  G. Cohen,et al.  Receptor-mediated Endocytosis Is Not Required for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis* , 2007, Journal of Biological Chemistry.

[47]  L. Zitvogel,et al.  Cell death modalities: classification and pathophysiological implications , 2007, Cell Death and Differentiation.

[48]  A. Tolcher,et al.  Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  A. Ashworth,et al.  LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. , 2007, Anticancer research.

[50]  F. Chan,et al.  Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. , 2007, Cytokine.

[51]  P. Croucher,et al.  INVESTIGATING THE INTERACTION BETWEEN OSTEOPROTEGERIN AND RANKL OR TRAIL: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS , 2007 .

[52]  D. Heath,et al.  An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. , 2007, Cancer research.

[53]  B. Sipos,et al.  TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma , 2006, Oncogene.

[54]  J. Schulte am Esch,et al.  TRAIL-R4-beta: a new splice variant of TRAIL-receptor 4 lacking the cysteine rich domain 1. , 2006, Biochemical and biophysical research communications.

[55]  E. Solary,et al.  Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2 , 2006, Molecular and Cellular Biology.

[56]  R. Bataille,et al.  Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. , 2006, Blood.

[57]  D. Lawrence,et al.  Death-receptor activation halts clathrin-dependent endocytosis , 2006, Proceedings of the National Academy of Sciences.

[58]  R. Khosravi‐Far,et al.  Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. , 2006, Cancer research.

[59]  Andreas Untergasser,et al.  Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs , 2006, Clinical Cancer Research.

[60]  G. Gores,et al.  Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[61]  G. Screaton,et al.  Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Cross,et al.  Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival? , 2005, Breast Cancer Research and Treatment.

[63]  F. Berrino,et al.  Childhood cancer survival trends in Europe: a EUROCARE Working Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  R. Zeillinger,et al.  Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer , 2005, Molecular Cancer Research.

[65]  E. D. de Vries,et al.  Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus , 2004, Annals of the rheumatic diseases.

[66]  Robin Foà,et al.  TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. , 2005, Haematologica.

[67]  C. Belka,et al.  Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis , 2005, BMC Cancer.

[68]  A. El-Zawahry,et al.  Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts , 2005, BMC Cancer.

[69]  A. Ruggeri,et al.  Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. , 2004, International journal of oncology.

[70]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[71]  D. Tyrrell,et al.  TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice , 2004, Cancer Research.

[72]  C. Thiele,et al.  Interferon γ Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis–Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing’s Sarcoma , 2004, Cancer Research.

[73]  Hao Shen,et al.  Reduced Apoptosis and Ameliorated Listeriosis in TRAIL-Null Mice1 , 2004, The Journal of Immunology.

[74]  G. Screaton,et al.  Following a TRAIL: Update on a ligand and its five receptors , 2004, Cell Research.

[75]  W. El-Deiry,et al.  Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[76]  I. Holen,et al.  Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis , 2004, Breast Cancer Research and Treatment.

[77]  F. Hamdy,et al.  Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL‐Induced Apoptosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[78]  C. Rodríguez-Galindo.  Pharmacological management of Ewing sarcoma family of tumours , 2004, Expert opinion on pharmacotherapy.

[79]  A. Evdokiou,et al.  Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin. , 2004, International journal of oncology.

[80]  S. Korsmeyer,et al.  Review Cell Death: Critical Control Points Another Line of Evidence for the Importance of Caspases in Cell Death Came From , 2022 .

[81]  L. Lenz,et al.  TRAIL-R as a negative regulator of innate immune cell responses. , 2004, Immunity.

[82]  C. Thiele,et al.  Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. , 2004, Cancer research.

[83]  J. Mizuguchi,et al.  Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor‐related apoptosis‐inducing ligand‐induced caspase‐8 activation, apoptosis and loss of mitochondrial membrane potential , 2003, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[84]  A. Evdokiou,et al.  Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy , 2003, British Journal of Cancer.

[85]  J. Lünemann,et al.  TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis , 2003, The Lancet.

[86]  A. Ashkenazi,et al.  Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. , 2003, Cytokine & growth factor reviews.

[87]  P. Secchiero,et al.  TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways , 2003, Circulation.

[88]  M. MacFarlane.  TRAIL-induced signalling and apoptosis. , 2003, Toxicology letters.

[89]  P. Croucher,et al.  Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. , 2003, Cancer research.

[90]  YOUHAI H. Chen,et al.  Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice , 2003, Nature Immunology.

[91]  A. Evdokiou,et al.  Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail‐induced apoptosis , 2002, International journal of cancer.

[92]  F. Hamdy,et al.  Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. , 2002, Cancer research.

[93]  M. Smyth,et al.  Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.

[94]  M. Smyth,et al.  Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.

[95]  K. Totpal,et al.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.

[96]  S. Fulda,et al.  Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer , 2001, Oncogene.

[97]  T. Burns,et al.  Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo , 2001, Oncogene.

[98]  M. Nau,et al.  Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. , 2001, Gynecologic oncology.

[99]  C. Niemeyer,et al.  Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis , 2001, Cell Death and Differentiation.

[100]  I. Pollack,et al.  Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[101]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[102]  N. Mitsiades,et al.  Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. , 2001, Cancer research.

[103]  M. Eby,et al.  Cytotoxicity of Tumor Necrosis Factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines , 2001, Oncogene.

[104]  M. Smyth,et al.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.

[105]  K. Bhalla,et al.  Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. , 2001, Cancer research.

[106]  W. Winkelmann,et al.  Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor–related apoptosis‐inducing ligand (TRAIL) , 2000, International journal of cancer.

[107]  M. S. Lee,et al.  Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity* , 2000, The Journal of Biological Chemistry.

[108]  D. Lawrence,et al.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.

[109]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[110]  W. El-Deiry,et al.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.

[111]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[112]  Y. Gazitt.  TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells , 1999, Leukemia.

[113]  B. Oh,et al.  2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. , 1999, Immunity.

[114]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[115]  H. Kovar,et al.  The Ewing family of tumors and the search for the Achilles' heel. , 1999, Current opinion in oncology.

[116]  L. Ries,et al.  Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. , 1999, Journal of the National Cancer Institute.

[117]  E. Alnemri,et al.  Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. , 1999, Cancer research.

[118]  C. Maliszewski,et al.  Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL , 1999, The Journal of experimental medicine.

[119]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[120]  T. Griffith,et al.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.

[121]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[122]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[123]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[124]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[125]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[126]  J. Bell,et al.  TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL , 1997, Current Biology.

[127]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[128]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[129]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[130]  Matthias Mann,et al.  FLICE is activated by association with the CD95 death‐inducing signaling complex (DISC) , 1997, The EMBO journal.

[131]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[132]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[133]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[134]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[135]  J. Thompson,et al.  2 A crystal structure of an extracellular fragment of human CD40 ligand. , 1995, Structure.

[136]  S. Sprang,et al.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. , 1990, The Journal of biological chemistry.

[137]  R. Wilkins,et al.  Ewing's sarcoma of bone. Experience with 140 patients , 1986, Cancer.

[138]  L. Ackerman,et al.  Chondrosarcoma of bone , 1952, Cancer.

[139]  H. Jaffe,et al.  Ewing's Sarcoma of Bone. , 1947, The American journal of pathology.